Nerve stimulator

A nerve stimulator. The nerve stimulator includes: a mid-shell, a stimulation acquisition module mounted within the mid-shell, a feed-through component being disposed on an end surface of the mid-shell and being electrically connected to the stimulation acquisition module, a mounting cover being mounted on the end surface of the mid-shell and covering an outer side of the feed-through component, and a flexible electrode being connected to one side of the feed-through component toward the mounting cover and extending from the end surface to an side surface of the mid-shell. The nerve stimulator of the embodiment of the present disclosure adopts a miniature installation design, which effectively reduces damage to tissues and facilitates the expansion of the number of electrode channels. In addition, the overall sealing property of the device is significantly improved by the multi-layer sealing structure.

The abstract as published by the patent office, from US12434062B1. It describes the invention; it is not a statement of what is protected.

• Interface and electrodes

  Electrodes and arrays · Peripheral interfaces

• Packaging

  Packaging and hermeticity · Connectors and feedthroughs

• Stimulation

  Stimulation

What the filing appears to be about, read by published rules from its title, abstract and classification codes (A61N1/02, A61N1/05, A61N1/0551, A61N1/3605, A61N1/36062). The claims define what a patent protects, and they are not read here.

Interface and electrodes

Everything downstream works with what the contacts pick up. Their number, size and distance from the neurons set the ceiling on the signal. The problem behind it: more contacts, closer to neurons, that still record after years in tissue that reacts to them.

Packaging

Body fluid destroys unprotected electronics. An implant meant to last has to stay sealed for years while passing every channel through its wall. The problem behind it: a seal that lasts as long as the patient needs it, at a size that leaves room for the channels.

Stimulation

Restoring sensation, sight or movement needs information going in, and a therapy that adapts needs to sense and stimulate at once. The problem behind it: evoking a precise, stable effect without damaging tissue or electrodes, and without blinding the recording.

Why the layer matters to the field, not a judgement of this filing. A patent family shows that protection was sought. It does not show that the technology was built, is used in a product, or works in people. The whole stack

One invention, published 3 times in 2 offices. Each publication opens in Espacenet.

• ChinaCN118903675A8 Nov 2024CN118903675B6 Dec 2024 · grant
• United StatesUS12434062B17 Oct 2025 · grant

1. 10 Oct 2024First filingEarliest priority, at China. The family is counted in this year.
2. 8 Nov 2024First publicationCN118903675A, China.
3. 6 Dec 2024Grant publishedCN118903675B, China.
4. 21 May 2025ApplicationFiled at United States.
5. 7 Oct 2025Grant publishedUS12434062B1, United States.

Dates as the offices published them. Office records are in the offices' own words and are a selection: refusals, lapses and withdrawals, and records that name an owner. Each concerns one member of the family, not the family as a whole, and another member in the same office may stand. Whether a patent is in force today is not assessed.

Organisation

BCIFlex · 24 families identified

• Bibliographic data, family members and office records: European Patent Office, Open Patent Services (the DOCDB and INPADOC databases), read 7 Oct 2026.
• The record itself, with its claims and description: US12434062B1 in Espacenet
• Counted as a BCI patent family: classified A61N1/36 (electrical stimulation therapy); filed by 北京智冉医疗科技有限公司, an organisation already in the graph; describes neural hardware or methods without naming the field. How families are found and judged